ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

November 24, 2017: By Jon Swedien

ProQRProQR Therapeutics announced Nov. 13 that the first patient has been dosed in its Phase I/II open-label trial of QR-110, a proposed treatment for Leber’s congenital amaurosis 10 (LCA 10).

The trial will enroll about six adults and six children who have LCA 10 due to a p.Cys998X mutation in the CEP290 gene, ProQR said. Subjects will receive a dose of QR-110 every three months for a total of four doses in one eye.

The trial is being conducted at the University of Iowa in Iowa City, Iowa; the Scheie Eye Institute at the University of Pennsylvania in Philadelphia; and Ghent University Hospital in Ghent, Belgium.

LCA 10 is caused by mutations in the CEP290 gene, of which the p.Cys998X mutation is the most common. It leads to early loss of vision, causing most people to lose their sight in the first few years of life. To date, there are no approved treatments or other products in clinical development that treat the underlying cause of the disease, ProQR said.

QR-110 is ProQR’s lead program in the ophthalmology pipeline. The pipeline also includes two programs for Usher syndrome, a program for Fuchs endothelial corneal dystrophy, and a program for Stargardt disease. QR-110 is ProQR’s second program to enter clinical development. It follows QR-010, which is being developed for the most common mutation causing cystic fibrosis.

Netherlands-based ProQR said at the end of Q3-2017 that it had $46.6 million on hand. The company said it raised about $20 million from an issuance of ordinary shares in November that will fund operations through potential clinical data readouts in three different programs.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023